Market Overview

Analyst Says Tilray Growth Expectations Are Way Too High

Share:
Analyst Says Tilray Growth Expectations Are Way Too High
Read more about our latest Cannabis News! CANNABIS HOME

Cannabis stocks are getting high praise from Wall Street analysts lately, with several top companies landing new buy ratings. Unfortunately for Tilray Inc (NASDAQ: TLRY) investors, yet another analyst said Thursday he is staying on the sidelines when it comes to the stock.

The Analyst

Stifel analyst W. Andrew Carter initiated Tilray with a Hold rating and C$37 ($27.62) price target.

The Thesis

While Carter is bullish on top cannabis pick Canopy Growth Corp (NYSE: CGC), Carter said Tilray shares don’t look cheap even after a 50.3 percent year-to-date sell-off.

Need more cannabis news? Check out all of our coverage here.

Carter is forecasting Tilray will generate some impressive revenue growth over the next two years, expanding annual sales from $70 million to nearly $500 million by fiscal 2021. Unfortunately, $500 million is well below consensus analyst estimates of $600 million, and the stock is already pricing in extreme long-term growth.

Tilray management has said long-term consumer packaged goods gross margins will be at least 50 percent and adjusted EBITDA margins will be at least 25 percent. Carter said these targets may be ambitious given the nature of the business.

“While Tilray’s asset light approach reduces the capital intensity and provides flexibility, we believe the intense regulatory demands of this category could pressure margins in the future and we believe this model presents some risk to being able to fully capitalize on global opportunities which we believe suggest a less fulsome valuation relative to its capital intensive peers,” Carter wrote in the note.

Carter’s lukewarm initiation comes just one day after Oppenheimer analyst Rupesh Parikh initiated coverage of Tilray with a Perform rating and said the “full valuation” will cap the stock’s rebound potential in the near-term.

Price Action

Tilray shares traded lower by another 1.7 percent to $34.96 on Thursday.

Related Links:

Analyst Likes Cronos, But Valuation Suggests 'Downside Potential'

Stifel Cautious On Aurora Cannabis Given 'Lack Of A Definitive Strategy' In US

Latest Ratings for TLRY

DateFirmActionFromTo
Jul 2019Initiates Coverage OnNeutral
Jun 2019Initiates Coverage OnOverweight
Jun 2019Initiates Coverage OnNeutral

View More Analyst Ratings for TLRY
View the Latest Analyst Ratings

Read more about our latest Cannabis News! CANNABIS HOME

Posted-In: Stifel W. Andrew CarterAnalyst Color Cannabis Price Target Initiation Markets Analyst Ratings Best of Benzinga

 

Related Articles (CGC + TLRY)

View Comments and Join the Discussion!

Cannabis Movers

Sign up for our secret cannabis newsletter!
Never miss out on the breaking news in the Cannabis Industry!

The Obamas Are Bringing Podcasts To Spotify

What To Make Of Costco's May Sales